Publications in collaboration with researchers from Philipp University of Marburg (27)

2024

  1. G protein-specific mechanisms in the serotonin 5-HT2A receptor regulate psychosis-related effects and memory deficits

    Nature communications, Vol. 15, Núm. 1, pp. 4307

  2. PsyCog: A computerised mini battery for assessing cognition in psychosis

    Schizophrenia Research: Cognition, Vol. 37

  3. Type 1 Autoimmune Pancreatitis in Europe: Clinical Profile and Response to Treatment

    Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 5, pp. 994-1004.e10

2023

  1. Corrigendum to “Dissecting the genetic heterogeneity of gastric cancer” (eBioMedicine (2023) 92, (S2352396423001810), (10.1016/j.ebiom.2023.104616))

    eBioMedicine

  2. Dissecting the genetic heterogeneity of gastric cancer

    eBioMedicine, Vol. 92

2022

  1. Correction to: Training During the COVID-19 Lockdown: Knowledge, Beliefs, and Practices of 12,526 Athletes from 142 Countries and Six Continents (Sports Medicine, (2022), 52, 4, (933-948), 10.1007/s40279-021-01573-z)

    Sports Medicine

  2. How to Succeed as an Athlete: What We Know, What We Need to Know

    International Journal of Sports Physiology and Performance

  3. Training During the COVID-19 Lockdown: Knowledge, Beliefs, and Practices of 12,526 Athletes from 142 Countries and Six Continents

    Sports Medicine, Vol. 52, Núm. 4, pp. 933-948

2021

  1. Editorial: The Immunological Implications of the Hygiene Hypothesis

    Frontiers in Immunology

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2018

  1. Prognosis of sporadic resected small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors – a multi-institutional study

    HPB, Vol. 20, Núm. 3, pp. 251-259

2017

  1. Magnetothermal genetic deep brain stimulation of motor behaviors in awake, freely moving mice

    eLife, Vol. 6

  2. POLE and POLD1 screening in 155 patients with multiple polyps and early-onset colorectal cancer

    Oncotarget, Vol. 8, Núm. 16, pp. 26732-26743

2016

  1. Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy

    Movement Disorders, Vol. 31, Núm. 5, pp. 742-747

2015

  1. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013

    The Lancet, Vol. 385, Núm. 9963, pp. 117-171

  2. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: Quantifying the epidemiological transition

    The Lancet, Vol. 386, Núm. 10009, pp. 2145-2191

  3. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013

    The Lancet, Vol. 386, Núm. 9995, pp. 743-800

  4. Model Driven Optimization of Magnetic Anisotropy of Exchange-Coupled Core-Shell Ferrite Nanoparticles for Maximal Hysteretic Loss

    Chemistry of Materials, Vol. 27, Núm. 21, pp. 7380-7387

2014

  1. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy

    Movement Disorders, Vol. 29, Núm. 4, pp. 470-478

  2. Differential activity of GSK-3 isoforms regulates NF-κB and TRAIL- or TNFα induced apoptosis in pancreatic cancer cells

    Cell Death and Disease, Vol. 5, Núm. 3